0000320017-26-000032
SEC filingLisata Therapeutics reported a narrower Q1 2026 operating loss of -$4.9M, improving 15.5% YoY, driven by moderated expenses despite elevated G&A from the proposed Kuva Labs acquisition. Net loss improved 5.0% to -$4.5M with EPS at -$0.50, while cash burn slowed significantly to -$3.1M.
Lisata Therapeutics, Inc. (LSTA) reported Q1 2026 results showing sequential improvement in loss metrics amid ongoing clinical development and a pending acquisition. The GAAP operating loss narrowed to -$4.9 million from -$5.8 million in Q1 2025, a 15.5% year-over-year reduction. This progress reflects disciplined cost management in a capital-constrained biotech environment, where R&D and G&A expenses are scrutinized closely to extend runway.
Net income followed suit, improving to -$4.5 million from -$4.7 million YoY (5.0% better), with diluted EPS at -$0.50 versus -$0.55 (9.1% improvement). These gains demonstrate the company's ability to moderate its burn rate without compromising core operations, providing a clearer path to value inflection points in its pipeline.
Cash flow dynamics improved markedly, with net cash used in operating activities dropping to -$3.1 million from -$5.4 million YoY. Free cash flow aligned exactly at -$3.1 million, supported by zero capital expenditures in the period (down from $28K prior year). This moderation in cash burn is critical for Lisata, as it preserves liquidity during a transformative phase.
Looking ahead, Lisata will continue evaluating uncertain tax positions, while emphasizing the imperative to raise capital. With no unregistered equity sales reported and a focus on the acquisition process, investors should monitor progress on the Kuva deal for potential financing or strategic shifts. These results position the company to navigate acquisition uncertainty while advancing its therapeutic objectives, though capital access remains the defining risk.